TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Bowel CLEAnsing: A National Initiative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients~* 18 years or older~* Able to comprehend the trial~* Have an indication for full colonoscopy~Exclusion Criteria:~Subjects are excluded from enrollment into the study if any of the following are present:~General exclusion criteria:~* Subject refusal~* Previous bowel preparation in the last 14 days~* Pregnancy or breastfeeding~* Reduced mobility~Medical/Endoscopic exclusion criteria:~* Suspected or diagnosed with bowel obstruction~* Any colonic surgery~* Toxic megacolon~* Ileus~* Ischemic colitis~* Decompensated heart failure~* Severe acute renal failure~* Severe liver disease~* Severe electrolyte imbalance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue (Type: ACTIVE_COMPARATOR): None
- 1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue (Type: ACTIVE_COMPARATOR): None
- 1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Early colonoscopy; 2) High-dose, day before; 3)Low residue (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid (Type: ACTIVE_COMPARATOR): None
- 1) Later colonoscopy; 2) Low volume day before; 3)Low residue (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Appropriate degree of weakness for age, creatine kinase greater than 20 times the upper limit of normal, and genetic mutation known to be causative for Duchenne muscular dystrophy .~2. Appropriate degree of weakness for age, creatine kinase greater than 20 times the upper limit of normal and genetic or biopsy confirmation of Duchenne muscular dystrophy in a primary relative (e.g. brother or maternal uncle).~3. De-identified, genetic studies will be reviewed by collaborator Kevin Flanigan, MD prior to enrollment of subjects.~4. Age at entry: one month through 30 months.~Exclusion Criteria:~* Prior treatment with corticosteroids

- Gender: MALE
- Minimum Age: 1 Month
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- Oral Prednisolone (Type: EXPERIMENTAL): Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>17 years~2. Microbiologically-confirmed septic arthritis~3. At least one surgical drainage/lavage~Exclusion Criteria:~1. Presence of osteosynthesis material in the vicinity of the articulation~2. Presence of a concomitant infection needing more than 2 week's of antibiotic therapy~3. More than 3 surgical drainages~4. Life expectancy less than 6 months~5. Chronic osteomyelitis in vicinity of the arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Two week's arm - surgery (Type: EXPERIMENTAL): The investigators perform a surgical drainage and removal of the infected orthopedic implant.
- Four week's arm - surgery (Type: ACTIVE_COMPARATOR): The investigators surgically remove the infected implant.
- Two week's arm - drugs (Type: EXPERIMENTAL): The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
- Four week's arm - drugs (Type: ACTIVE_COMPARATOR): The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Faecal Microbiota Transplantation in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ulcerative colitis \>3 months duration~* Active mild-moderate ulcerative colitis (Mayo 4-10)~* Ulcerative colitis of any extent except isolated proctitis \< 5cm~* Live within driving distance of clinical site (to attend multiple study visits)~Exclusion Criteria:~* Pregnancy~* Active gastrointestinal infection~* Other gastrointestinal disease / comorbidities~* Prior colonic surgery~* Recent antibiotic or probiotic use~* Prednisone \> 20mg~* Monoclonal antibody immunosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FMT infusions (Type: ACTIVE_COMPARATOR): FMT infusions constituted from stool provided by healthy, screened donors
- Placebo arm (Type: PLACEBO_COMPARATOR): Placebo infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female Subjects able to give consent~* Post partum patients~* Baseline Hgb \< /= 10 g/dL~* Agree to practice birth control~Exclusion Criteria:~* Participation in previous clinical trial of this investigational agent~* Known hypersensitivity reaction to active control~* Significant vaginal bleeding~* History of anemia other than iron deficiency anemia~* Anticipated need for surgery during the study~* Active severe infection or malignancy~* Known positive Hepatitis B antigen of Hepatitis C viral antibody~* Known HIV antibodies~* Received an investigational drug within 30 days of screening~* Alcohol abuse within past 6 months~* Hemochromatosis or other iron storage disorders~* Significant cardiovascular disease~* Any laboratory abnormality, medical condition or severe psychiatric disorder which in the opinion of the investigator woud put the subject's disease management at risk or may result in the subject being able to comply with the study requirements

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected patients.~2. Age 18 or more.~3. Antiretroviral treatment containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) plus 1 Non-nucleoside reverse-transcriptase inhibitor (NNRTI) or 1 protease inhibitor (PI) or 1 integrase inhibitor (ININ)~4. Patients receiving stable antiretroviral treatment for at least 6 months.~5. Viral load under 50 copies/mL in the last 6 months~6. Patients with CCR5 tropism based in V3 genotyping in proviral DNA using the G2P with a false positive rate of 10% interpretation method.~7. A change of treatment is needed due to toxicity / tolerability problems with the 3rd drug (PI, NNRTI or ININ), according to investigator criteria.~8. An antiretroviral regimen containing a CCR5-antagonist is suitable for the patient (physician criteria).~9. Voluntary written informed consent.~Exclusion Criteria:~1. Pregnancy or breast-feeding.~2. Patient previously treated with maraviroc.~3. Patients with documented resistance to maraviroc or any other drug considered for the new ARV regimen.~4. Viral failure in the moment of inclusion.~5. Bad adherence history or anticipated (investigator criteria).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Change of 3rd drug to maraviroc (Type: EXPERIMENTAL): Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of neuromyelitis optica spectrum disorder based on the recent guidelines in 2015~* Expanded disability status scale between 0 and 7~* Age between 18 and 50 years old~Exclusion Criteria:~* Pregnancy or lactation during the study~* Deciding to leave the study by patient~* Lack of consent to enter the study~* Lack of cooperation for follow up~* Severe side effect of the medication~* Treatment with other immunosuppressant medications (including but not limited to cyclophosphamide, mycophenolate mofetil, methotrexate, others) within two months before intervention~* Taking any other immunosuppressant or other type of medication (including herbal drugs) without permission of the physician during the study.~* Presence of other autoimmune disease (including but not limited to Behcet disease, systemic lupus erythematosus, rheumatoid arthritis, and others)~* Presence of liver disorders~* Presence of hematologic disorders~* Presence of heart failure~* Receipt of a live vaccine within 4 weeks prior to intervention~* Previous treatment with Azathioporine or Rituximab~* History of HIV, hepatitis B, or hepatitis C~* Ongoing daily steroid use~* History of severe allergic or anaphylactic reaction to monoclonal antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Azathioprine (Type: EXPERIMENTAL): Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
- Rituximab (Type: EXPERIMENTAL): Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Gallopamil in Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged more than 18 years~* Written informed consent~* Diagnosis of severe asthma according to ATS criteria~Exclusion Criteria:~* Smoker or former smoker~* Chronic viral infections (hepatitis, HIV)~* Aspergillosis~* Pregnancy~* Breastfeeding~* Contraindications to gallopamil or bronchoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 16 patients with a diagnosis of severe asthma under gallopamil treatment
- 2 (Type: PLACEBO_COMPARATOR): 16 patients with a diagnosis of severe asthma under placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children and adolescents between 10-17 years, in good physical health, preferentially with a primary schizophrenia spectrum diagnosis or bipolar spectrum disorder~Exclusion Criteria:~* History of mental retardation~* Any neurological disorder with the exception of Pervasive Developmental Disorder (PDD), Attention Deficit Hyperactivity Disorder (ADHD), and Tourette's Syndrome

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.~* Outpatients aged 18 through 74 years at the time of consent~* Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.~Exclusion Criteria:~* Patients with imminent risk of suicide or injury to self, others, or property.~* Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.~* Patients who are otherwise considered ineligible for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): once daily orally
- SM-13496 20 - 60 mg/day (Type: EXPERIMENTAL): once daily orally
- SM-13496 80 - 120 mg/day (Type: EXPERIMENTAL): once daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of TD-9855 to Treat Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia (FM)~  * Informed consent~ * 18 to 65 years of age~ * Discontinue therapy with adrenergic-acting drugs, and certain other medications~    * Only acetaminophen or NSAID as rescue pain medication~   * No narcotic pain meds or benzodiazepines~   * Only non-benzodiazepines as rescue hypnotics~Exclusion Criteria:~* Any current psychiatric disorder, lifetime bipolar disorder, severe comorbid Axis II disorder, mental retardation, etc, as assessed by Mini International Neuropsychiatric Interview (MINI)~* Major depression at screening by MINI when unable to be washed out of MDD meds (investigator or provider's judgment)~* Risk of suicide (investigator opinion and/or C-SSRS)~* Recent history of substance or alcohol abuse~* BMI \<18 or ≥45~* Concurrent disease; pain for diagnosed illness other than FM; non-compliance; history of seizures; pheochromocytoma; glaucoma; CV disease; orthostatic hypotension or orthostatic tachycardia; untreated sleep apnea~* Abnormal lab values (liver, kidney, thyroid, and others)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TD-9855 Group 1 (Type: EXPERIMENTAL): Group 1 to be dosed with TD-9855
- TD-9855 Group 2 (Type: EXPERIMENTAL): Group 2 to be dosed with TD-9855
- Placebo (Type: PLACEBO_COMPARATOR): Group to be dosed with Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diabetic patients~Exclusion Criteria:~* history of intraocular surgery or laser treatment,~* any ocular diseases that might affect pupil size such as glaucoma,uveitis,Horner's syndrome, Adies' pupil,~* history of allergy to any drug used, and~* hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Analogues and Severe Hypoglycaemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes for 5 years.~* Age\>18 years.~* Two or more episodes of hypoglycaemia during the last year,~Exclusion Criteria:~* History of Addisons disease~* Growth hormone deficiency or untreated myxoedema~* CVD within 6 months~* Cancer within 5 years~* Alcohol or drug abuse~* Pregnant or lactating women~* Fertile women without effective contraception~* Participation in another trial within 30 days~* Inability to understand the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): HUman Insulin
- 2 (Type: EXPERIMENTAL): Analogue insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients who consent to the study entry on their free will before starting any trial-related activities.~2. Patients who participated in Study 231 and completed the required evaluation period (10 weeks).~3. Patients who are certainly and voluntarily able to participate in this study and record their seizures by themselves or have family members or caregivers (or nurses, if hospitalized) record the seizures. Patients who wish to continue perampanel treatment and necessitate receiving the long- term administration judged by the investigator or sub-investigator.~Exclusion criteria:~1. Pregnant or lactating women, women of child-bearing potential, women willing to become pregnant.~2. Patients who are ineligible judged by the investigator or sub investigator in light of medical history or complication at enrollment in treatment period.~3. Patients who operate heavy equipment or drive should not be recruited into the study.~4. Patients who are ineligible for study entry judged by the investigator or sub-investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Perampanel (Type: EXPERIMENTAL): Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) \[NCT00849212\]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete